Iovance Biotherapeutics Sustainability Profile
Iovance Biotherapeutics, Inc., a pioneering leader in the field of cell therapy, is headquartered in the United States, with significant operations across various regions. Founded in 2011, the company has made remarkable strides in developing innovative treatments for cancer, particularly through its unique tumour-infiltrating lymphocyte (TIL) therapy. This groundbreaking approach harnesses the body’s immune system to target and destroy cancer cells, setting Iovance apart in the biopharmaceutical industry. With a strong focus on advancing personalised cancer therapies, Iovance has achieved notable milestones, including successful clinical trials and collaborations that enhance its market position. The company’s flagship product, Lifileucel, exemplifies its commitment to transforming cancer treatment, offering hope to patients with advanced melanoma and other solid tumours. As Iovance continues to expand its influence, it remains dedicated to improving patient outcomes through innovative therapeutic solutions.
DitchCarbon Score
How does Iovance Biotherapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Iovance Biotherapeutics's score of 25 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Iovance Biotherapeutics's reported carbon emissions
Iovance Biotherapeutics, headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges from the company. This lack of data suggests that Iovance Biotherapeutics may not have established formal commitments to reduce carbon emissions or may not have publicly disclosed such information. In the context of the biotherapeutics industry, companies are increasingly recognising the importance of sustainability and climate action. While Iovance Biotherapeutics has not yet outlined its climate commitments or reduction initiatives, the industry as a whole is moving towards greater transparency and accountability regarding carbon emissions. As the company continues to develop its sustainability strategy, stakeholders may look for future disclosures that align with industry standards and expectations for climate action.
How Carbon Intensive is Iovance Biotherapeutics's Industry?
How Carbon Intensive is Iovance Biotherapeutics's Location?
Iovance Biotherapeutics's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Iovance Biotherapeutics has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
